Orbimed Advisors LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $11.4 Million - $16.6 Million	420,000 Added 131.39%	739,651 $21.2 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $2.42 Million - $3.54 Million	-114,000 Reduced 26.29%	319,651 $9.78 Million
Q3 2023 Nov 14, 2023	BUY	$26.2 - $36.08 $8.3 Million - $11.4 Million	316,651 Added 270.64%	433,651 $11.7 Million
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $2.94 Million - $4.84 Million	117,000 New	117,000 $4.17 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $2.26 Million - $3.49 Million	-68,100 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $1.4 Million - $4.3 Million	68,100 New	68,100 $1.96 Million

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.